The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Somatostatin Analogue Drug Market Research Report 2025
Synopsis
Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
The global Somatostatin Analogue Drug market was valued at US$ 5960 million in 2023 and is anticipated to reach US$ 9467.8 million by 2030, witnessing a CAGR of 6.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Somatostatin Analogue Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin Analogue Drug.
Report Scope
The Somatostatin Analogue Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Somatostatin Analogue Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Somatostatin Analogue Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Octreotide
Lanreotide
Pasireotide
Segment by Application
Acromegaly
Neuroendocrine Tumor (NET)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Somatostatin Analogue Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
The global Somatostatin Analogue Drug market was valued at US$ 5960 million in 2023 and is anticipated to reach US$ 9467.8 million by 2030, witnessing a CAGR of 6.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Somatostatin Analogue Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin Analogue Drug.
Report Scope
The Somatostatin Analogue Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Somatostatin Analogue Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Somatostatin Analogue Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Octreotide
Lanreotide
Pasireotide
Segment by Application
Acromegaly
Neuroendocrine Tumor (NET)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Somatostatin Analogue Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Octreotide
1.2.3 Lanreotide
1.2.4 Pasireotide
1.3 Market by Application
1.3.1 Global Somatostatin Analogue Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Acromegaly
1.3.3 Neuroendocrine Tumor (NET)
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Somatostatin Analogue Drug Market Perspective (2019-2030)
2.2 Somatostatin Analogue Drug Growth Trends by Region
2.2.1 Global Somatostatin Analogue Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Somatostatin Analogue Drug Historic Market Size by Region (2019-2024)
2.2.3 Somatostatin Analogue Drug Forecasted Market Size by Region (2025-2030)
2.3 Somatostatin Analogue Drug Market Dynamics
2.3.1 Somatostatin Analogue Drug Industry Trends
2.3.2 Somatostatin Analogue Drug Market Drivers
2.3.3 Somatostatin Analogue Drug Market Challenges
2.3.4 Somatostatin Analogue Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Somatostatin Analogue Drug Players by Revenue
3.1.1 Global Top Somatostatin Analogue Drug Players by Revenue (2019-2024)
3.1.2 Global Somatostatin Analogue Drug Revenue Market Share by Players (2019-2024)
3.2 Global Somatostatin Analogue Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Somatostatin Analogue Drug Revenue
3.4 Global Somatostatin Analogue Drug Market Concentration Ratio
3.4.1 Global Somatostatin Analogue Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Somatostatin Analogue Drug Revenue in 2023
3.5 Somatostatin Analogue Drug Key Players Head office and Area Served
3.6 Key Players Somatostatin Analogue Drug Product Solution and Service
3.7 Date of Enter into Somatostatin Analogue Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Somatostatin Analogue Drug Breakdown Data by Type
4.1 Global Somatostatin Analogue Drug Historic Market Size by Type (2019-2024)
4.2 Global Somatostatin Analogue Drug Forecasted Market Size by Type (2025-2030)
5 Somatostatin Analogue Drug Breakdown Data by Application
5.1 Global Somatostatin Analogue Drug Historic Market Size by Application (2019-2024)
5.2 Global Somatostatin Analogue Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Somatostatin Analogue Drug Market Size (2019-2030)
6.2 North America Somatostatin Analogue Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Somatostatin Analogue Drug Market Size by Country (2019-2024)
6.4 North America Somatostatin Analogue Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Somatostatin Analogue Drug Market Size (2019-2030)
7.2 Europe Somatostatin Analogue Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Somatostatin Analogue Drug Market Size by Country (2019-2024)
7.4 Europe Somatostatin Analogue Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Somatostatin Analogue Drug Market Size (2019-2030)
8.2 Asia-Pacific Somatostatin Analogue Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Somatostatin Analogue Drug Market Size (2019-2030)
9.2 Latin America Somatostatin Analogue Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Somatostatin Analogue Drug Market Size by Country (2019-2024)
9.4 Latin America Somatostatin Analogue Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Somatostatin Analogue Drug Market Size (2019-2030)
10.2 Middle East & Africa Somatostatin Analogue Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Camurus AB
11.1.1 Camurus AB Company Detail
11.1.2 Camurus AB Business Overview
11.1.3 Camurus AB Somatostatin Analogue Drug Introduction
11.1.4 Camurus AB Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.1.5 Camurus AB Recent Development
11.2 Chiasma
11.2.1 Chiasma Company Detail
11.2.2 Chiasma Business Overview
11.2.3 Chiasma Somatostatin Analogue Drug Introduction
11.2.4 Chiasma Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.2.5 Chiasma Recent Development
11.3 Ipsen Group
11.3.1 Ipsen Group Company Detail
11.3.2 Ipsen Group Business Overview
11.3.3 Ipsen Group Somatostatin Analogue Drug Introduction
11.3.4 Ipsen Group Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.3.5 Ipsen Group Recent Development
11.4 Boehringer Ingelheim International GmbH
11.4.1 Boehringer Ingelheim International GmbH Company Detail
11.4.2 Boehringer Ingelheim International GmbH Business Overview
11.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Introduction
11.4.4 Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.4.5 Boehringer Ingelheim International GmbH Recent Development
11.5 Eli Lilly & Co.
11.5.1 Eli Lilly & Co. Company Detail
11.5.2 Eli Lilly & Co. Business Overview
11.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Introduction
11.5.4 Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.5.5 Eli Lilly & Co. Recent Development
11.6 F. Hoffmann-La Roche Ltd.
11.6.1 F. Hoffmann-La Roche Ltd. Company Detail
11.6.2 F. Hoffmann-La Roche Ltd. Business Overview
11.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Introduction
11.6.4 F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.6.5 F. Hoffmann-La Roche Ltd. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Somatostatin Analogue Drug Introduction
11.7.4 Novartis AG Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.7.5 Novartis AG Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Somatostatin Analogue Drug Introduction
11.8.4 Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.8.5 Pfizer Inc. Recent Development
11.9 Tarveda Therapeutics Inc.
11.9.1 Tarveda Therapeutics Inc. Company Detail
11.9.2 Tarveda Therapeutics Inc. Business Overview
11.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Introduction
11.9.4 Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.9.5 Tarveda Therapeutics Inc. Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Somatostatin Analogue Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Octreotide
Table 3. Key Players of Lanreotide
Table 4. Key Players of Pasireotide
Table 5. Global Somatostatin Analogue Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Somatostatin Analogue Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Somatostatin Analogue Drug Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Somatostatin Analogue Drug Market Share by Region (2019-2024)
Table 9. Global Somatostatin Analogue Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Somatostatin Analogue Drug Market Share by Region (2025-2030)
Table 11. Somatostatin Analogue Drug Market Trends
Table 12. Somatostatin Analogue Drug Market Drivers
Table 13. Somatostatin Analogue Drug Market Challenges
Table 14. Somatostatin Analogue Drug Market Restraints
Table 15. Global Somatostatin Analogue Drug Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Somatostatin Analogue Drug Market Share by Players (2019-2024)
Table 17. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2023)
Table 18. Ranking of Global Top Somatostatin Analogue Drug Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Somatostatin Analogue Drug Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Somatostatin Analogue Drug Product Solution and Service
Table 22. Date of Enter into Somatostatin Analogue Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Somatostatin Analogue Drug Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Somatostatin Analogue Drug Revenue Market Share by Type (2019-2024)
Table 26. Global Somatostatin Analogue Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Somatostatin Analogue Drug Revenue Market Share by Type (2025-2030)
Table 28. Global Somatostatin Analogue Drug Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Somatostatin Analogue Drug Revenue Market Share by Application (2019-2024)
Table 30. Global Somatostatin Analogue Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Somatostatin Analogue Drug Revenue Market Share by Application (2025-2030)
Table 32. North America Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Somatostatin Analogue Drug Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Somatostatin Analogue Drug Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Somatostatin Analogue Drug Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Somatostatin Analogue Drug Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Somatostatin Analogue Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Somatostatin Analogue Drug Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Somatostatin Analogue Drug Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2025-2030) & (US$ Million)
Table 47. Camurus AB Company Detail
Table 48. Camurus AB Business Overview
Table 49. Camurus AB Somatostatin Analogue Drug Product
Table 50. Camurus AB Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 51. Camurus AB Recent Development
Table 52. Chiasma Company Detail
Table 53. Chiasma Business Overview
Table 54. Chiasma Somatostatin Analogue Drug Product
Table 55. Chiasma Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 56. Chiasma Recent Development
Table 57. Ipsen Group Company Detail
Table 58. Ipsen Group Business Overview
Table 59. Ipsen Group Somatostatin Analogue Drug Product
Table 60. Ipsen Group Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 61. Ipsen Group Recent Development
Table 62. Boehringer Ingelheim International GmbH Company Detail
Table 63. Boehringer Ingelheim International GmbH Business Overview
Table 64. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product
Table 65. Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 66. Boehringer Ingelheim International GmbH Recent Development
Table 67. Eli Lilly & Co. Company Detail
Table 68. Eli Lilly & Co. Business Overview
Table 69. Eli Lilly & Co. Somatostatin Analogue Drug Product
Table 70. Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 71. Eli Lilly & Co. Recent Development
Table 72. F. Hoffmann-La Roche Ltd. Company Detail
Table 73. F. Hoffmann-La Roche Ltd. Business Overview
Table 74. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product
Table 75. F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 76. F. Hoffmann-La Roche Ltd. Recent Development
Table 77. Novartis AG Company Detail
Table 78. Novartis AG Business Overview
Table 79. Novartis AG Somatostatin Analogue Drug Product
Table 80. Novartis AG Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 81. Novartis AG Recent Development
Table 82. Pfizer Inc. Company Detail
Table 83. Pfizer Inc. Business Overview
Table 84. Pfizer Inc. Somatostatin Analogue Drug Product
Table 85. Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 86. Pfizer Inc. Recent Development
Table 87. Tarveda Therapeutics Inc. Company Detail
Table 88. Tarveda Therapeutics Inc. Business Overview
Table 89. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product
Table 90. Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 91. Tarveda Therapeutics Inc. Recent Development
Table 92. Teva Pharmaceutical Industries Ltd. Company Detail
Table 93. Teva Pharmaceutical Industries Ltd. Business Overview
Table 94. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product
Table 95. Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2019-2024) & (US$ Million)
Table 96. Teva Pharmaceutical Industries Ltd. Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Somatostatin Analogue Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Somatostatin Analogue Drug Market Share by Type: 2023 VS 2030
Figure 3. Octreotide Features
Figure 4. Lanreotide Features
Figure 5. Pasireotide Features
Figure 6. Global Somatostatin Analogue Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Somatostatin Analogue Drug Market Share by Application: 2023 VS 2030
Figure 8. Acromegaly Case Studies
Figure 9. Neuroendocrine Tumor (NET) Case Studies
Figure 10. Others Case Studies
Figure 11. Somatostatin Analogue Drug Report Years Considered
Figure 12. Global Somatostatin Analogue Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Somatostatin Analogue Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Somatostatin Analogue Drug Market Share by Region: 2023 VS 2030
Figure 15. Global Somatostatin Analogue Drug Market Share by Players in 2023
Figure 16. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Somatostatin Analogue Drug Revenue in 2023
Figure 18. North America Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Somatostatin Analogue Drug Market Share by Country (2019-2030)
Figure 20. United States Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Somatostatin Analogue Drug Market Share by Country (2019-2030)
Figure 24. Germany Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Somatostatin Analogue Drug Market Share by Region (2019-2030)
Figure 32. China Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Somatostatin Analogue Drug Market Share by Country (2019-2030)
Figure 40. Mexico Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Somatostatin Analogue Drug Market Share by Country (2019-2030)
Figure 44. Turkey Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Somatostatin Analogue Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Camurus AB Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 47. Chiasma Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 48. Ipsen Group Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 49. Boehringer Ingelheim International GmbH Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 50. Eli Lilly & Co. Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 51. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 52. Novartis AG Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 53. Pfizer Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 54. Tarveda Therapeutics Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 55. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
